Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) affect approximately 900,000 people in the United States each year. The incidence of DVT in trauma patients may range from 5% to 63% depending on the patient's risk factors and type of prophylaxis. Therefore, an aggressive approach to prevention of thromboembolism is warranted on the trauma service.
PHARMACOLOGIC PROPHYLAXIS
Multiple agents exist for prophylaxis. The two most common at this institution are low dose Heparin (LDH) and low molecular weight Heparin (LMWH). First line pharmacologic prophylaxis should be with LMWH as it has been found to be more efficacious in preventing thromboembolism in the trauma population.
Pharmacologic prophylaxis should be used Uin addition to SCDsU in all patients unless there is a significant bleeding risk or for the few exceptions such as isolated hand or minor face fractures.
1. UDoseU: LMWH (Enoxaparin) -30 mg SQ bid 2. UContraindicationU: LMWH should not be used with renal insufficiency or failure. In this case, the patient should be treated with LDH 5,000 units SQ bid or tid.
VENA CAVA FILTERS
The classic indications for vena cava filter (VCF) placement are in patients with an acute proximal DVT who had a contraindication to receive Heparin, who had a bleeding complication during Heparin treatment, or who had a PE despite appropriate anticoagulation. There is no level I or level II recommendation about insertion of a prophylactic VCF. However, the Eastern Association for the Surgery of Trauma supports insertion of a prophylactic filter in patients considered very high risk for DVT/PE who must be immobilized for a long period of time and cannot receive anticoagulation because of increased bleeding risks.
SCREENING
Universal scheduled ultrasound screening for asymptomatic DVT is not supported in the literature. Patients that were admitted to an outside hospital for several days and subsequently transferred to our trauma center Ushould be consideredU for a screening ultrasound.
Also, patients that were unable to have any prophylaxis within the first week of admission should be considered for a screening ultrasound.
TRAUMA/NEUROSURGERY PATIENTS WITH HIGH RISK FOR BLEEDING COMPLICATIONS
Where pharmacological prophylaxis is contraindicated the following guidelines apply:
a. Neurosurgery patients: where there is a concern for active bleeding or re-bleeding and pharmacologic prophylaxis may be contraindicated initiate mechanical prophylaxis. Pharmacologic prophylaxis (LMWH) is to be reassessed q 24 hours and may be initiated when there are no clinical or radiological signs of active bleeding. b. Trauma patients: where there is concern for ongoing bleed, where pharmacologic prophylaxis is currently contraindicated, start with mechanical prophylaxis and reassess q 24 hours for clinical signs of active bleeding. When risk of bleeding has decreased to low, use LMWH.
